DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kangsan | ko |
dc.contributor.author | Choe, Donghui | ko |
dc.contributor.author | Song, Yoseb | ko |
dc.contributor.author | Kang, Minjeong | ko |
dc.contributor.author | Lee, Seung-Goo | ko |
dc.contributor.author | Lee, Dae-Hee | ko |
dc.contributor.author | Cho, Byung-Kwan | ko |
dc.date.accessioned | 2021-11-17T06:41:10Z | - |
dc.date.available | 2021-11-17T06:41:10Z | - |
dc.date.created | 2021-11-16 | - |
dc.date.created | 2021-11-16 | - |
dc.date.created | 2021-11-16 | - |
dc.date.issued | 2021-11 | - |
dc.identifier.citation | METABOLIC ENGINEERING, v.68, pp.174 - 186 | - |
dc.identifier.issn | 1096-7176 | - |
dc.identifier.uri | http://hdl.handle.net/10203/289195 | - |
dc.description.abstract | Bacteroides thetaiotaomicron represents a major symbiont of the human gut microbiome that is increasingly viewed as a promising candidate strain for microbial therapeutics. Here, we engineer B. thetaiotaomicron for heterologous production of non-native butyrate as a proof-of-concept biochemical at therapeutically relevant concentrations. Since B. thetaiotaomicron is not a natural producer of butyrate, we heterologously expressed a butyrate biosynthetic pathway in the strain, which led to the production of butyrate at the final concentration of 12 mg/L in a rich medium. Further optimization of butyrate production was achieved by a round of metabolic engineering guided by an expanded genome-scale metabolic model (GEM) of B. thetaiotaomicron. The in silico knock-out simulation of the expanded model showed that pta and ldhD were the potent knock-out targets to enhance butyrate production. The maximum titer and specific productivity of butyrate in the pta-ldhD double knockout mutant increased by nearly 3.4 and 4.8 folds, respectively. To our knowledge, this is the first engineering attempt that enabled butyrate production from a non-butyrate producing commensal B. thetaiotaomicron. The study also highlights that B. thetaiotaomicron can serve as an effective strain for live microbial therapeutics in human. | - |
dc.language | English | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.title | Engineering Bacteroides thetaiotaomicron to produce non-native butyrate based on a genome-scale metabolic model-guided design | - |
dc.type | Article | - |
dc.identifier.wosid | 000711623700002 | - |
dc.identifier.scopusid | 2-s2.0-85117202931 | - |
dc.type.rims | ART | - |
dc.citation.volume | 68 | - |
dc.citation.beginningpage | 174 | - |
dc.citation.endingpage | 186 | - |
dc.citation.publicationname | METABOLIC ENGINEERING | - |
dc.identifier.doi | 10.1016/j.ymben.2021.10.005 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.contributor.localauthor | Cho, Byung-Kwan | - |
dc.contributor.nonIdAuthor | Lee, Seung-Goo | - |
dc.contributor.nonIdAuthor | Lee, Dae-Hee | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Bacteroides thetaiotaomicron | - |
dc.subject.keywordAuthor | Genome-scale metabolic model | - |
dc.subject.keywordAuthor | Flux-balance analysis | - |
dc.subject.keywordAuthor | Butyrate | - |
dc.subject.keywordAuthor | Commensal microbes | - |
dc.subject.keywordPlus | ESCHERICHIA-COLI | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | KNOCKOUT STRATEGIES | - |
dc.subject.keywordPlus | ACETATE METABOLISM | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | FRAGILIS | - |
dc.subject.keywordPlus | BACTERIA | - |
dc.subject.keywordPlus | FLUX | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | MICROBIOME | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.